Oligometastatic breast cancer: old to new entity, outcome and treatment algorithm

Post neoadjuvant management in BRCA mutant breast cancer patients

The 2022 OncoAlert Colloquium Day 6: EONS Sessions

The 2022 OncoAlert Colloquium Day 5: GI Oncology

The 2022 OncoAlert Colloquium Day 4: ESGO Sessions and Gynaecological Oncology

The 2022 OncoAlert Colloquium Day 3: Lung Cancer

The 2022 OncoAlert Colloquium Day 2: GU Oncology

The 2022 OncoAlert Colloquium Day 1: Breast Cancer

NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy in locally advanced rectal cancer

HER-Vaxx is safe and provides clinical benefit over standard of care chemo for patients with HER2-overexpressing gastric cancer

Zolbetuximab + mFOLFOX6 as 1L treatment shows significantly prolonged PFS and OS in CLDN18.2+/ HER2 mG/GEJ adenocarcinoma

OPERA: Nonoperative modality (NOM) treatments of rectal cancer do not compromise the chance of cure